VAPRED Study

Jump to navigation Jump to search

D-Dimer Microchapters

Home

Patient information

Overview

Historical Perspective

Physiology

Clinical Correlation

Causes of High D-dimer

Diagnostic Role in Thromboembolism

Prognostic Role in Mortality

Prognostic Role in Thromboembolism Occurence

Prognostic Role in Thromboembolism Recurrence

Prognostic Role in Non-Thromboembolism

Clinical Trials

Landmark Trials

Case #1

VAPRED Study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VAPRED Study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VAPRED Study

CDC on VAPRED Study

VAPRED Study in the news

Blogs on VAPRED Study

Directions to Hospitals Treating D-dimer

Risk calculators and risk factors for VAPRED Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Official Title

Study of Predictive Echo Doppler Score and D-dimer Level in Evaluation of the Thromboembolic Event Recurrence After Anticoagulant Treatment Cessation

Objective

The purpose of this trial is to perform a prospective multicentric study to determine predictive ED score and D-dimer level in the evaluation of the thromboembolic event recurrence after anticoagulant treatment cessation

University Hospital, Grenoble

Timeline

Timeline
Start Date March 2005
End Date May 2010
Status phase 4

The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00860106 .

Study Description

Study Description
Study Type Interventional
Study Phase Phase 4
Study Design
Allocation Non-Randomized
Endpoint Safety Study
Interventional Model Single Group Assignment
Masking Open Label
Study Details
Primary Purpose Prevention
Condition Previous Vka Treatment
Previous Proximal VTE
Intervention Echo Doppler (ED), DDimers and phone follow up
ED score, DDimers level and phone questionnary
Study Arms Follow up
ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).
Phone follow up for 2 years.
Intervention: Other: ED, DDimers and phone follow up
Population Size 222

The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00860106 .

Eligibility Criteria

Inclusion Criteria

  • >18 and <80 years old
  • First or second treated proximal VTE event (+/- Pulmonary embolism)
  • Signed informed consent

Exclusion Criteria

  • Active cancer or currently treated
  • Previous VTE>2
  • Long term anticoagulant treatment for VTE diseases
  • Long term anticoagulant treatment for other diseases
  • Pregnancy, parturient or breast feeding
  • Person deprived of freedom by judicial or administrative decision
  • Consent unsigned

Outcomes

Primary Outcomes

VTE event recurrence [ Time Frame: 0-2 years ] [ Designated as safety issue: Yes ]

Secondary Outcomes

Not provided

Publications

Results

Conclusion

References

Template:WH Template:WS